Esomeprazole

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Gastrointestinal Hemorrhage

Conditions

Gastrointestinal Hemorrhage

Trial Timeline

Oct 1, 2005 → Dec 1, 2007

NCT ID

NCT00251979

About Esomeprazole

Esomeprazole is a phase 3 stage product being developed by AstraZeneca for Gastrointestinal Hemorrhage. The current trial status is completed. This product is registered under clinical trial identifier NCT00251979. Target conditions include Gastrointestinal Hemorrhage.

What happened to similar drugs?

6 of 20 similar drugs in Gastrointestinal Hemorrhage were approved

Approved (6) Terminated (4) Active (10)

🔄Intralipid + ICI35,868 (Diprivan) + ICI35,868 (Diprivan) + EES0000645/A (SDS)Johnson & JohnsonPhase 3

✅Remimazolam TosilateJiangsu Hengrui MedicineApproved

❌Famitinib capsules + Sunitinib CapsulesJiangsu Hengrui MedicinePhase 3

🔄Esomeprazole IV + Omeprazole IVAstraZenecaPhase 3

🔄Durvalumab + FLOT chemotherapyAstraZenecaPhase 3

🔄EsomeprazoleAstraZenecaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01370538	Phase 3	Completed	Aug 1, 2011	Oct 1, 2011	Heartburn
NCT01370525	Phase 3	Completed	Aug 1, 2011	Oct 1, 2011	Heartburn
NCT00474019	Phase 1	Completed	Oct 1, 2007	Oct 1, 2009	Pharmacokinetics
NCT00427635	Phase 3	Completed	Oct 1, 2006	Apr 1, 2009	GERD
NCT00384592	Approved	Completed	Sep 1, 2006	May 1, 2007	Gastro-Oesophageal Reflux Disease
NCT00318968	Approved	Completed	May 1, 2006	Nov 1, 2007	GERD
NCT00608712	Approved	Completed	Nov 1, 2005	Aug 1, 2006	Postoperative Bariatric Surgery
NCT00251979	Phase 3	Completed	Oct 1, 2005	Dec 1, 2007	Gastrointestinal Hemorrhage
NCT00392002	Approved	Completed	Oct 1, 2005	May 1, 2007	Gastroesophageal Reflux
NCT00242736	Approved	Completed	Oct 1, 2005	Jan 1, 2006	GERD
NCT00291746	Approved	Completed	Sep 1, 2005	Nov 1, 2006	Gastroesophageal Reflux
NCT00206440	Phase 3	Terminated	Aug 1, 2005	Feb 1, 2012	Nausea
NCT00243724	Phase 3	Completed	Apr 1, 2005	Jun 1, 2007	Gastroesophageal Reflux
NCT00524251	Pre-clinical	Completed	Jun 1, 2004	Mar 1, 2008	GERD
NCT00251966	Phase 3	Completed	May 1, 2004	Sep 1, 2005	Gastroesophageal Reflux
NCT00251901	Phase 3	Completed	May 1, 2004	Jul 1, 2005	Chest Pain
NCT00120315	Approved	Completed	Dec 1, 2003	Mar 1, 2007	Dyspepsia
NCT00574925	Approved	Completed	Nov 1, 2003	Oct 1, 2007	Gastroesophageal Reflux Disease (GERD)
NCT00222131	Phase 2	Completed	Oct 1, 2003	Jan 1, 2008	Indigestion
NCT00318084	Approved	Completed	Jan 1, 2003	—	GERD

Competing Products

20 competing products in Gastrointestinal Hemorrhage

See all competitors

Product	Company	Stage	Hype Score
Raludotatug Deruxtecan (R-DXd)	Daiichi Sankyo	Phase 2	39
Patritumab deruxtecan	Daiichi Sankyo	Phase 1/2	39
DS-6157a	Daiichi Sankyo	Phase 1	21
DS-8201a + Physician's Choice	Daiichi Sankyo	Phase 2	35
Naldemedine + Placebo	Shionogi	Phase 2	27
Gemcitabine	Eli Lilly	Phase 1/2	32
Olaratumab	Eli Lilly	Phase 2	27
pemetrexed + cisplatin	Eli Lilly	Phase 2	35
cetuximab	Eli Lilly	Phase 2	35
BBI503	Sumitomo Pharma	Phase 2	27
BBI608 + Fluorouracil + Oxaliplatin + Leucovorin + Irinotecan + Bevacizumab + Capecitabine + Regorafenib	Sumitomo Pharma	Phase 1/2	32
Intralipid + ICI35,868 (Diprivan) + ICI35,868 (Diprivan) + EES0000645/A (SDS)	Johnson & Johnson	Phase 3	40
Placebo + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol)	Johnson & Johnson	Phase 2	35
Remimazolam Tosilate	Jiangsu Hengrui Medicine	Approved	43
Famitinib capsules + Sunitinib Capsules	Jiangsu Hengrui Medicine	Phase 3	32
Famitinib	Jiangsu Hengrui Medicine	Phase 2	31
Esomeprazole IV + Omeprazole IV	AstraZeneca	Phase 3	40
Durvalumab + FLOT chemotherapy	AstraZeneca	Phase 3	44
Esomeprazole	AstraZeneca	Phase 3	40
AZD2171	AstraZeneca	Phase 2	35